Jump to content

Philadelphia chromosome

From Wikipedia, the free encyclopedia
(Redirected from Bcr-abl fusion protein)
Philadelphia chromosome
A metaphase cell positive for the bcr/abl rearrangement using FISH
SpecialtyOncology Edit this on Wikidata

The Philadelphia chromosome or Philadelphia translocation (Ph) is an abnormal version of chromosome 22 where a part of the Abelson murine leukemia 1 (ABL1) gene on chromosome 9 breaks off and attaches to the breakpoint cluster region (BCR) gene in chromosome 22.[1][2] The balanced reciprocal translocation between the long arms of 9 and 22 chromosomes [t (9; 22) (q34; q11)] results in the fusion gene BCR::ABL1.[2] The oncogenic protein with persistently enhanced tyrosine kinase (TK) activity transcribed by the BCR::ABL1 fusion gene can lead to rapid, uncontrolled growth of immature white blood cells that accumulates in the blood and bone marrow.[3][1]

The Philadelphia chromosome is present in the bone marrow cells of a vast majority chronic myelogenous leukemia (CML) patients. The expression patterns off different BCR-ABL1 transcripts vary during the progression of CML. Each variant is present in a distinct leukemia phenotype and can be used to predict response to therapy and clinical outcomes. The Ph is also observed in patients with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), and mixed-phenotype acute leukemia.[1][3]

Molecular biology

[edit]
Schematic of the Philadelphia chromosome formation, showcasing exons in the ABL1 and BCR gene, and the central breakpoint regions[4]

The chromosomal abnormality in the Philadelphia chromosome from the reciprocal translocation t(9;22)(q34;q11), is the result of fragments from chromosomes 9 and 22 swapping places.[3] The ABL proto-oncogene 1 on chromosome 9, from region q34, is juxtaposed with a portion of the BCR gene on chromosome 22, region q11.2.[5] The derivative chromosome 22 produced by this translocation is known as the Philadelphia chromosome. This translocation creates a fusion gene, BCR::ABL1, which codes for a constitutively (“always on”) active tyrosine kinase signaling protein, driving uncontrolled cell division.[6][3]

The formation of the Philadelphia chromosome is due to the fusion of the BCR and ABL1 genes. ABL1 is derived from Abelson murine leukemia, a retrovirus that causes leukemia and lymphoma in mice. It is named after Herbert T. Abelson, who discovered it in 1970.[7][8][9] BCR stands for breakpoint cluster region because of the relatively small genomic region where the DNA breaks occurred.[9] The fusion can happen at different points in the BCR gene, where the gene will fuse with exon 2 of ABL (breakpoints in exon 3 of ABL1 have also been observed, but they are less frequent). The BCR::ABL1 oncogene exists in three primary isoforms depending on the breakpoint site of the BCR gene and are named after the region of the fuse, and the molecular weight of the transcribed BCR-ABL1 fusion protein, and all encode for a tyrosine kinase protein. The e1a2 transcript is a fusion between exon 1 of BCR, also called the minor breakpoint region (m-BCR), and exon 2 of ABL1 and encodes a oncoprotein of 185-190kDa, referred to as P190.[10][11] BCR::ABL1 is associated with around 20-30% of all philadelphia chromosome positive B-cell ALL (ph+ B-ALL) and is the most genetic subgroup of B-ALL. The incident rate for ALL is age related, as the incident rate increases to 50% for ALL in patients aged 50 years and older. where P190 is associated with 60-80% of these.[5][6][12] The e13a2 and e14a2 transcripts found in the major breakpoint region (M-BCR), which consists of exons 12 through 16. These transcripts encode for a oncoprotein of size 210kDa, and is referred to as P210. P210 is associated with over 95% of CML cases, with a 50/50 split between the e13a2 and e14a2 variants. Additionally, e13a2 and e14a2 has been found to be co-expressed in an estimated 5-10% of CML patients. P210 is also found to be present in 40% of adult and 10% of child B-ALL cases.[13] CML has an incidence of 50 cases per million per year[14] Lastly, the e19a2 transcript, located in the μ-BCR region, produces a oncoprotein of 230kDa which is referred to as P230. This variant is uncommon in comparison, and has been linked to the rare disease called chronic neutrophilic leukemia (CNL), which falls under mixed-phenotype acute leukemias.[14]

Detection of these variants is carried out using methods such as sanger sequencing, reverse transcription polymerase chain reaction (RT-PCR), qPCR, Flourescense In Situ Hybridization (FISH), and southern blotting.[13] Many laboratories however are working on incorporating Next Generation Sequencing (NGS) into their routine diagnostic analysis as NGS technology is rapidly improving , and will in the near future enable full clinical sequencing of the entire gene.[10]

The normal BCR gene is ubiquitously expressed cytoplasmic protein with many known functionalities. ABL1 gene expresses a membrane-associated protein, a nonreceptor protein-tyrosine kinase. ABL1 is linked to multiple processes related to cell growth and survival, such as cytoskeleton and actin remodelling, and inhibition of cell cycle progression. ABL1 can also be found translocated in the nucleus and has DNA binding capabilities, as it is involved in DNA damage control and repair, and apoptosis. The BCR-ABL1 transcript is also translated into a tyrosine kinase containing domains from both the BCR and ABL1 genes. The activity of tyrosine kinases is typically regulated in an auto-inhibitory fashion, but the BCR-ABL1 fusion gene codes for a protein that is constitutively activated, leading to impaired DNA binding and unregulated cell division (i.e. cancer).[15][16]

Mechanisms

[edit]

The formation of the BCR::ABL1 oncogene leads to a constitutively active Tyrosine kinase, which is important for transformation of hematopoietic cells. Kinases are enzymes that add phosphate groups to their substrates. In cell biology and cell signalling, phosphorylated substrates are mainly used as a “on” signal, usually setting in motion a cascade of downstream signalling pathways. The high activity of TK leads to a chronic activation of signalling pathways associated with all stages of cell transformation. Resulting in uncontrolled cell proliferation, blocked cell differentiation, and inhibited apoptosis. Meaning cells with the BCR::ABL1 fusion multiply uncontrollably, without differentiating into mature white blood cells that live longer due to a lack of apoptosis promoting signals. This leads to a buildup of these immature white blood cells in the bloodstream[14][17] There are several signalling pathways associated with the BCR::ABL1 pathogenesis, such as: the Mitogen-activated protein kinase (MAPK/RAS) pathway, PI3K-AKT-mTOR (PAM) pathway, Janus kinase (JAK) - Signal transducers and activators of transcription (STAT) pathway and the Protein Phosphatase 2A (PP2A) tumour suppressor gene –β-catenin pathway.

MAPK Pathway

Overview map of enzymes which comprises and are impacted by the RAS pathway[18]

The MAPK pathway includes several key signalling components, and phosphorylation events known to play a crucial part in carcinogenesis. MAPK is comprised of multiple signalling cascades, of which the RAS-RAF-MEK-ERK signalling pathway can be found. This pathway is known to play a vital role in cell development, proliferation and survival. Mutations in, and abnormal activation of this pathway will induce tumours, being present in 30% of all cancers. BCR::ABL1 fusions will create constitutively active tyrosine kinases. BCR::ABL1 contains a kinase domain containing Tyr 177, which is a binding site for growth factor receptor binding protein 2 (GBR2). BGR2 binds to a protein called son of sevenless (SOS), a guanine nucleotide exchange factor (GEF). SOS facilitates the conversion of inactive RAS-GDP to active RAS-GTP, which turns on the cascade of enzymes which the RAS-RAF-MEK-ERK pathway is comprised of. All steps in this pathway are phosphorylation of enzyme downstream of the signalling pathway, which ends with ERK which in turn phosphorylates hundreds of substrates in the cytoplasm and nucleus which regulate many cellular processes including proliferation, survival, and growth.[19][20][18] The RAS/RAF/MEK/ERK pathway is also implicated in overexpression of osteopontin (OPN), which is important for maintenance of the hematopoietic stem cell niche, which indirectly influences unchecked proliferation characteristic of leukemic cells. The RAS-MAPK pathway is associated with many types of cancers, including CML and ph+ ALL, being also linked to imatinib resistance in some cases.[14]

PI3K-AKT-mTOR (PAM) pathway

Overview map of enzymes which comprises and are impacted by the PI3K pathway[21]

Associated with cell survival, growth and cell cycle, the PAM signalling pathway plays a central role in both CML, ALL, other leukemias and solid tumours, being found in around 50% of all cancers. Normally the PAM signalling pathway maintains and controls growth factors in all higher eukaryotic cells in response to external stimuli. Hyperactivation of this pathway therefore promotes pro-survival intracellular signalling via the PAM pathway, inducing drug resistance.[22] In cancer cells, the PAM pathway gets stimulated by receptors like G-protein-coupled receptors (GPCR), and receptor tyrosine kinases (RTKs), among others. It is especially through the RTKs that cells with the BCR::ABL1 fusion, the PAM pathway is activated. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3). The phosphorylation of PIP2 to PIP3 activates AKT, which has numerous downstream signalling targets, related to cellular processes. Additionally, mTOR can act both upstream and downstream of AKT. Two multiprotein complexes of mTOR are involved in the PAM pathway, mTORC1 and mTORC2 which both regulate protein synthesis required for cell growth, angiogenesis, and proliferation. mTORC2 stimulates AKT activity, which in turn amplifies activity of mTORC1 by supressing mTORC1 inhibitors. BCR::ABL1 activation of the PAM pathway may additionally also occur by binding of two proteins, Crkl and c-Cbl, to the ABL fragment of the fusion oncoprotein. The BCR::ABL1 kinase protein will phosphorylate c-Cbl which will activate PI3K.[23][21]

JAK-STAT pathway

The JAK-STAT pathway is an evolutionary conserved signalling pathway involved over 50 cytokines and growth factors are associated with this pathway. Playing an important role in haematopoiesis, differentiation, immune modulation and apoptosis. In healthy cells, JAK proteins naturally phosphorylate each other, prompting a STAT protein to bind to the JAK tyrosine phosphorylated domain. The STAT protein is in turn itself phosphorylated by JAK. STAT is separated from JAK, followed by a translocation of STAT from the cytosol to the nucleus. In the nucleus STAT will induce transcriptional activation of specific genes and other downstream targets.[24] JAK2, STAT1, STAT3 and STAT5 have been shown to be constitutively active in CML models. Where JAK2 and STAT5 being the main components, where BCR::ABL1 enhances the JAK2-STAT5 pathway to enable oncogenic transformation. JAK2 has been shown to phosphorylate the Y177 domain on the BCR::ABL1 oncoprotein, which increases protein stability. JAK2 induces expression of the oncogene c-MYC, which is overexpressed in BCR::ABL1 positive cells, and is a downstream target for activated JAK2 proteins in these cells. STAT 5 is crucial for development and survival of lymphoid leukemia cells, by regulating transcription of anti-apoptotic BCL proteins. c-MYC additionally enables the transactivation of the survivin promoter via JAK2-PI3K pathways, indicating a complex connection between these pathways. STAT5 is not essential for normal haematopoiesis, making it a good therapeutic target in ph+ leukemias.[3][25]

PP2A tumour suppressor gene –β-catenin pathway

PP2A is a tumour-suppressor gene which constitutes 0,2% to 1% of total proteins found in mammalian cells, tasked with numerous processes, such as signal transduction, DNA replication, protein translation, regulating cell proliferation, cell cycle progression and differentiation. Studies have shown that in patients with the BCR::ABL1 translocation, BCR::ABL1 fusion protein promotes loss of PP2A function; effectively turning off the tumour suppressor gene. The mechanism for this pathway, involving BCR::ABL1, is complex, involving both the JAK/STAT pathway, and the Wnt/β-catenin pathway. The BCR::ABL1 tyrosine kinase will promote activation of JAK2, which in turn enhances β-catenin activity. β-catenin, a part of the Wnt/ β-catenin pathway associated with cancers unrelated directly to BCR::ABL1, induces inactivation of PP2A via a protein called SET (also known as Inhibitor-2 of PP2A). SET acts as a potent inhibitor of PP2A, turning off PP2A’s tumour suppressive activity. Counterintuitively, inhibition of PP2A has been shown to sensitize TKI-resistant cancer cells, making PP2A a target for therapies.[25][26][27][28]

Apoptosis

Programmed cell death, apoptosis, is controlled by several different mechanisms and pathways involving many enzymes and proteins. Disruption of these mechanisms can lead to loss of apoptotic function in a damaged cell, a hallmark characteristic of cancers. BCR::ABL1 encoded tyrosine kinase can impact both pro-apoptotic and anti-apoptotic proteins via different pathways. An important pro apoptotic is the p53 tumour suppressor, which reacts to DNA damage by inducing apoptosis. Related to p53 is p73, which encodes for multiple proteins through alternative splicing, and has a similar function to p53. Chemotherapeutic chemical cisplatin increases p73 levels in the cell, additionally cisplatin activates c-Abl tyrosine kinase, which enhances the pro-apoptotic ability of p73. c-Abl is activated by DNA damage, and regulates p73 through a c-Abl mechanism. BCR::ABL1 induces and MDM2 mRNA translation via a RNA binding protein. MDM2 negatively regulates p53 and p73 activity by targeting them for ubiquitination, a post translational process that recruits proteins to the proteasomes where they are degraded and recycled. Many chemotherapies are based on creating DNA damage to induce natural apoptosis, cancer cells with BCR::ABL1 are therefore more resistant to these chemotherapies.[29][30][31][32] Other main pathway for apoptosis resistance in BCR::ABL1 positive cancer cells is through the Bcl2 family of apoptotic regulatory proteins. BAD is a pro-apoptotic member of said protein family, when BAD is nonphosphorylated, it binds to the anti-apoptotic Bcl-XL and Bcl-2, promoting cell death. AKT and PI3K can phosphorylate BAD, preventing it from inhibiting anti-apoptotic Bcl-XL and Bcl-2, preventing cell death. AKT can also increase NF-κB activity by accelerating degradation of its inhibitor IκBα. This causes elevated Bcl-XL expression. The STAT5 pathway can also be involved, STAT5 can bind to the Bcl-x promoter, which increases expression of Bcl-XL further reinforcing resistance to apoptosis. Another pro-apoptotic is BAX, which plays a central role in mitochondria dependent apoptosis, is usually regulated by p53. In BCR::ABL1 patients p53 is usually heavily downregulated, resulting in low to no activation of BAX. It is theorised that TKI activity can be enhanced by inhibition of Bcl-2, as Bcl-2 normally prevents apoptosis by binding and inhibiting BAD and BAX.[30][33][34][35][36] All of these mechanisms attribute to the cell survival and drug resistance which is so characteristic for CML and ALL.[3]

Nomenclature

[edit]
Nomenclature Definition
BCR Breakpoint Cluster Region
ABL1 Abelson Tyrosine Kinase 1
Ph+ Philadelphia chromosome positive
Ph-like Similar gene expression profile to Ph+
t(9;22)(q34;q11)
t translocation
(9;22) exchange between chromosomes 9 and 22
q34 ABL1 gene on chromosome 9
q11.2 BCR gene on chromosome 22

Table 1. Philadelphia chromosome nomenclature defined by the BCR-ABL1 fusion gene, from a translocation between chromosomes 9 and 22 t(9;22)(q34;q11)[37][3][38].

Ph Type Protein Size Disease Association
P210 BCR-ABL1 210 kDa Classical CML, Ph+ ALL (~30%)
P190 BCR-ABL1 190 kDa Ph+ ALL (~70%), rare in CML
P230 BCR-ABL1 230 kDa Chronic Neutrophilic Leukemia (CNL), rare CML variant

Table 2. The size and disease association of the different BCR-ABL1 fusion proteins based on the breakpoints in the BCR and ABL1 genes[38].

Therapy

[edit]

The primary objective of Ph+ CML and ALL treatment is to improve survival rates to match the general population. A secondary objective, although achieved in fewer patients, is a deep molecular response (DMR), which can allow treatment discontinuation and lead to a treatment-free remission.[39]

The main treatment options for Ph+ leukemias are Tyrosine kinase inhibitors (TKIs), chemotherapy, often in combination with TKIs, and allogeneic treatments such as stem cell transplantation (HSCT). Chemotherapy is often used before stem cell transplantation in high-risk patients. HSCT is used for younger or high-risk patients who don’t respond well to TKIs.[39][6]

Tyrosine kinase inhibitors (TKIs)

[edit]
Figure A. Structural features of the Abl kinase domain important for activity and inhibitor binding. A) first generation TKI imatinib, B) second generation TKI dasatinib[40]

The BCR-ABL fusion gene produces an abnormal tyrosine kinase that drives Ph+ leukemia. TKIs target the BRC-ABL1 fusion protein and block the abnormal tyrosine kinase activity, preventing uncontrolled cell proliferation.[5] The first TKI was approved in the US in 2001, since 5 additional BCR::ABL1 TKIs have been approved by the US food and drug administration (FDA).[41] The TKIs are categorized in generations pertaining to potency, whereas each subsequent generation is effective to mutations with resistance to the previous generation.[39][41]

BCR::ABL1 TKI Generation
Imatinib First-generation
Dasatinib, Nilotinib, Bosutinib Second-generation
Ponatinib, Asciminib Third-generation

Table 3. FDA approved BCR::ABL1 TKIs categorized by generation[41].

The introduction of TKIs was initially alongside chemotherapy. Prior to TKIs, chemotherapy had been the standard treatment for Ph-positive leukemia with limited success and low, long-term survival rates.[41] The combination improved survival rates resulted in more patients achieving hematologic remission, where leukemia cells can no longer be detected in the blood. However, this approach had significant side effects, with some patients dying from complications during early phases of treatment.[6] Further research explored the use of TKIs with reduced-intensity chemotherapy and since 2004, clinical trials in Italy have used TKIs without chemotherapy during the first phase of treatment. This approach led to higher remission rates, fewer complications and eligibility for elderly patients unable to tolerate intense chemotherapy.[6]

Allogeneic transplantation and immunotherapy

[edit]

Based on the patient’s condition and response to TKIs, other treatment options such as Allogeneic Stem Cell Transplantation (HSCT) or immunotherapy. HSCT is primarily considered for younger patients or high-risk patients that do not respond well to TKIs. The process involves transplanting bone marrow stem cells from a matched donor and is infrequently used to treat CML due to long-term complications and risk factors.[6][41] Traditionally Allogeneic transplantation has been the standard curative treatment for Ph+ leukemia however, studies suggest it may not improve survival in patients without minimal residual disease (MRD). Immunotherapies are often considered in MRD cases or in instances of relapsed patients. Third generation, more potent TKIs and immunotherapies, may lead to fewer patients requiring transplantation as standard treatment. For patients with persistent MRD, TKI resistant mutations or multiple relapses, HSCT should be considered.[6] Depending on the stage of CML, cure rates with HSCT range from 20% to 60%. Improved techniques have reduced relapse free mortality rates after transplant to ~12% after 5 years and has made HSCT feasible for older patients.[41] Post-transplant, TKI maintenance therapy is recommended.[6]

Prognosis

[edit]

The introduction of BCR::ABL1 targeting TKIs significantly improved Ph+ CML prognosis. TKIs have increased the 10-year overall survival rate from less than 20% to 80%-85%. This has resulted in a similar 10-year relative survival rate for patients with CML and age-matched CML negative controls.[41]

History

[edit]

In 1960, the Philadelphia chromosome was co-discovered by cytogeneticists David Hungerford and Peter Nowell.[42][43] The at the time junior faculty member at the University of Pennsylvania School of Medicine Peter Nowell, through an accident managed to clearly see metaphase spreads in leukemic cells. This led him to seek the assistance of graduate student David Hungerford. Together they described an unusual, small chromosome present in leukocytes from patients with CML.[44][45] This finding provided strong evidence supporting Boveri’s hypothesis that a single genetic alteration could drive cancer development. While no other consistent chromosomal abnormalities were initially found in leukemias, the discovery of the Philadelphia chromosome marked a breakthrough in understanding cancer genetics.[46]

The mechanism for which the Philadelphia chromosome arises as a translocation, not a deletion was discovered by Janet Rowley in 1972, and subsequent paper was published in 1973. Rowley used Giemsa staining and quinacrine banding to show that the Ph chromosome resulted from a translocation between chromosomes 9 and 22. The presence of the t(9;22) translocation in nearly all bone marrow cells from CML patients implied that the abnormality was involved as a cause and not a result of the cancer.[44][45]

In 1984, Nora Heisterkamp and John Groffen later mapped the breakpoints on chromosomes 9 and 22, identifying the BCR on chromosome 22 and its fusion with the ABL gene from chromosome 9.[47] Owen Witte’s work demonstrated that the abnormal tyrosine kinase produced by BRC-ABL fusion gene had enhanced kinase activity. Experiments introducing the BCR-ABL gene in mice led to CML-like disease, proving its central role in leukemia development.[44]

Notes

Many of the sources used in this article referred to different statistics. For example, frequencies of the P190, P210 and P230 oncoproteins in CML and ph+ B-ALL. In this article, the % frequencies were set at an average value based on information from different sources. This discrepancy can probably be attributed to the fact that the review articles used here were based on different studies where frequencies were determined from populations used in the study. Random variations in detected frequency could therefore be to blame for this discrepancy.

Apart from the RAS-RAF, PI3K-AKT and JAK/STAT pathways, a certain source mentioned an additional pathway, the WNT/β-Catenin Pathway, that could also be involved in BCR::ABL1 related cancers. This was however excluded from this article, with exception to its part in the PP2A, due to a lack of good sources supporting this.

See also

[edit]

References

[edit]
  1. ^ a b c Sampaio, Mariana Miranda; Santos, Maria Luísa Cordeiro; Marques, Hanna Santos; Gonçalves, Vinícius Lima de Souza; Araújo, Glauber Rocha Lima; Lopes, Luana Weber; Apolonio, Jonathan Santos; Silva, Camilo Santana; Santos, Luana Kauany de Sá; Cuzzuol, Beatriz Rocha; Guimarães, Quézia Estéfani Silva; Santos, Mariana Novaes; de Brito, Breno Bittencourt; da Silva, Filipe Antônio França; Oliveira, Márcio Vasconcelos (2021-02-24). "Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review". World Journal of Clinical Oncology. 12 (2): 69–94. doi:10.5306/wjco.v12.i2.69. ISSN 2218-4333. PMC 7918527. PMID 33680875.
  2. ^ a b "Philadelphia Chromosome". www.cancer.gov. 2011-02-02. Retrieved 2025-03-26.
  3. ^ a b c d e f g Kang, Zhi-Jie; Liu, Yu-Fei; Xu, Ling-Zhi; Long, Zi-Jie; Huang, Dan; Yang, Ya; Liu, Bing; Feng, Jiu-Xing; Pan, Yu-Jia; Yan, Jin-Song; Liu, Quentin (December 2016). "The Philadelphia chromosome in leukemogenesis". Chinese Journal of Cancer. 35 (1): 48. doi:10.1186/s40880-016-0108-0. ISSN 1944-446X. PMC 4896164. PMID 27233483.
  4. ^ Abdulmawjood, Bilal; Costa, Beatriz; Roma-Rodrigues, Catarina; Baptista, Pedro V.; Fernandes, Alexandra R. (2021-11-19). "Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?". International Journal of Molecular Sciences. 22 (22): 12516. doi:10.3390/ijms222212516. ISSN 1422-0067. PMC 8626020. PMID 34830398.
  5. ^ a b c Komorowski, Lukasz; Fidyt, Klaudyna; Patkowska, Elżbieta; Firczuk, Malgorzata (2020-08-12). "Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities". International Journal of Molecular Sciences. 21 (16): 5776. doi:10.3390/ijms21165776. ISSN 1422-0067. PMC 7460962. PMID 32806528.
  6. ^ a b c d e f g h Foà, Robin; Chiaretti, Sabina (2022-06-22). "Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia". New England Journal of Medicine. 386 (25): 2399–2411. doi:10.1056/NEJMra2113347. ISSN 0028-4793. PMID 35731654.
  7. ^ Abelson, H. T.; Rabstein, L. S. (August 1970). "Lymphosarcoma: virus-induced thymic-independent disease in mice". Cancer Research. 30 (8): 2213–2222. ISSN 0008-5472. PMID 4318922.
  8. ^ Jabbour, Elias; Kantarjian, Hagop (November 2024). "Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring". American Journal of Hematology. 99 (11): 2191–2212. doi:10.1002/ajh.27443. ISSN 0361-8609. PMID 39093014.
  9. ^ a b Soverini, Simona; Mancini, Manuela; Bavaro, Luana; Cavo, Michele; Martinelli, Giovanni (2018-02-19). "Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy". Molecular Cancer. 17 (1): 49. doi:10.1186/s12943-018-0780-6. ISSN 1476-4598. PMC 5817796. PMID 29455643.
  10. ^ a b Soverini, Simona; Albano, Francesco; Bassan, Renato; Fabbiano, Francesco; Ferrara, Felicetto; Foà, Robin; Olivieri, Attilio; Rambaldi, Alessandro; Rossi, Giuseppe; Sica, Simona; Specchia, Giorgina; Venditti, Adriano; Barosi, Giovanni; Pane, Fabrizio (2020). "Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper". Cancer Medicine. 9 (9): 2960–2970. doi:10.1002/cam4.2946. ISSN 2045-7634. PMC 7196068. PMID 32154668.
  11. ^ Jacobs, Koen; Moerman, Alena; Vandepoele, Karl; Abeele, Tim Van den; De Mulder, Katrien; Steel, Eva; Clauwaert, Maxim; Louagie, Henk (October 2024). "Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia". International Journal of Laboratory Hematology. 46 (5): 910–917. doi:10.1111/ijlh.14320. ISSN 1751-5521. PMID 38840510.
  12. ^ Catalano, Gianfranco; Niscola, Pasquale; Banella, Cristina; Diverio, Daniela; Trawinska, Malgorzata Monika; Fratoni, Stefano; Iazzoni, Rita; De Fabritiis, Paolo; Abruzzese, Elisabetta; Noguera, Nelida Ines (2020-10-27). "NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of Literature". Mediterranean Journal of Hematology and Infectious Diseases. 12 (1): e2020083. doi:10.4084/mjhid.2020.083. ISSN 2035-3006. PMC 7643801. PMID 33194157.
  13. ^ a b Molica, Matteo; Abruzzese, Elisabetta; Breccia, Massimo (2020-08-29). "Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia". Mediterranean Journal of Hematology and Infectious Diseases. 12 (1): e2020062. doi:10.4084/mjhid.2020.062. ISSN 2035-3006. PMC 7485470. PMID 32952973.
  14. ^ a b c d Haider, Mobeen Z.; Anwer, Faiz (2025), "Genetics, Philadelphia Chromosome", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32809524, retrieved 2025-03-31
  15. ^ Osman, Afaf E.G.; Deininger, Michael W. (September 2021). "Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions". Blood Reviews. 49: 100825. doi:10.1016/j.blre.2021.100825. PMC 8563059. PMID 33773846.
  16. ^ Roskoski, Robert (April 2022). "Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia". Pharmacological Research. 178: 106156. doi:10.1016/j.phrs.2022.106156.
  17. ^ Sattlermc, Martin; Griffin, James D. (April 2003). "Molecular mechanisms of transformation by the BCR-ABL oncogene". Seminars in Hematology. 40 (2 Suppl 2): 4–10. doi:10.1053/shem.2003.50034. PMID 12783368.
  18. ^ a b Santarpia, Libero; Lippman, Scott M; El-Naggar, Adel K (January 2012). "Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy". Expert Opinion on Therapeutic Targets. 16 (1): 103–119. doi:10.1517/14728222.2011.645805. ISSN 1472-8222. PMC 3457779. PMID 22239440.
  19. ^ Al Hamad, Mohammad (2022-02-09). "Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review". F1000Research. 10: 1288. doi:10.12688/f1000research.74570.2. ISSN 2046-1402. PMC 8886173. PMID 35284066.
  20. ^ Vendramini, Elena; Bomben, Riccardo; Pozzo, Federico; Bittolo, Tamara; Tissino, Erika; Gattei, Valter; Zucchetto, Antonella (2022-01-28). "KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders". Cancers. 14 (3): 666. doi:10.3390/cancers14030666. ISSN 2072-6694. PMC 8833570. PMID 35158933.
  21. ^ a b Singh, Priyanka; Kumar, Veerandra; Gupta, Sonu Kumar; Kumari, Gudia; Verma, Malkhey (January 2021). "Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review". Medical Oncology. 38 (1): 10. doi:10.1007/s12032-021-01462-5. ISSN 1357-0560. PMID 33452624.
  22. ^ Kim, Hye Na; Ogana, Heather; Sanchez, Vanessa; Nichols, Cydney; Kim, Yong-Mi (2022), Dominguez-Villar, Margarita (ed.), "PI3K Targeting in Non-solid Cancer", PI3K and AKT Isoforms in Immunity, vol. 436, Cham: Springer International Publishing, pp. 393–407, doi:10.1007/978-3-031-06566-8_17, ISBN 978-3-031-06565-1, PMC 10075235, PMID 36243854
  23. ^ Glaviano, Antonino; Foo, Aaron S. C.; Lam, Hiu Y.; Yap, Kenneth C. H.; Jacot, William; Jones, Robert H.; Eng, Huiyan; Nair, Madhumathy G.; Makvandi, Pooyan; Geoerger, Birgit; Kulke, Matthew H.; Baird, Richard D.; Prabhu, Jyothi S.; Carbone, Daniela; Pecoraro, Camilla (2023-08-18). "PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer". Molecular Cancer. 22 (1): 138. doi:10.1186/s12943-023-01827-6. ISSN 1476-4598. PMC 10436543. PMID 37596643.
  24. ^ Liang, Dong; Wang, Qiaoli; Zhang, Wenbiao; Tang, Hailin; Song, Cailu; Yan, Zhimin; Liang, Yang; Wang, Hua (2024-01-26). "JAK/STAT in leukemia: a clinical update". Molecular Cancer. 23 (1): 25. doi:10.1186/s12943-023-01929-1. ISSN 1476-4598. PMC 10811937. PMID 38273387.
  25. ^ a b Amarante-Mendes, Gustavo P.; Rana, Aamir; Datoguia, Tarcila Santos; Hamerschlak, Nelson; Brumatti, Gabriela (2022-01-17). "BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia". Pharmaceutics. 14 (1): 215. doi:10.3390/pharmaceutics14010215. ISSN 1999-4923. PMC 8780254. PMID 35057108.
  26. ^ Lai, Damian; Chen, Min; Su, Jiechuang; Liu, Xiaohu; Rothe, Katharina; Hu, Kaiji; Forrest, Donna L.; Eaves, Connie J.; Morin, Gregg B.; Jiang, Xiaoyan (2018-02-07). "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemia". Science Translational Medicine. 10 (427). doi:10.1126/scitranslmed.aan8735. ISSN 1946-6234. PMID 29437150.
  27. ^ Neviani, Paolo; Harb, Jason G.; Oaks, Joshua J.; Santhanam, Ramasamy; Walker, Christopher J.; Ellis, Justin J.; Ferenchak, Gregory; Dorrance, Adrienne M.; Paisie, Carolyn A.; Eiring, Anna M.; Ma, Yihui; Mao, Hsiaoyin C.; Zhang, Bin; Wunderlich, Mark; May, Philippa C. (2013-10-01). "PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells". Journal of Clinical Investigation. 123 (10): 4144–4157. doi:10.1172/JCI68951. ISSN 0021-9738. PMC 3784537. PMID 23999433.
  28. ^ Neviani, Paolo; Santhanam, Ramasamy; Trotta, Rossana; Notari, Mario; Blaser, Bradley W.; Liu, Shujun; Mao, Hsiaoyin; Chang, Ji Suk; Galietta, Annamaria; Uttam, Ashwin; Roy, Denis C.; Valtieri, Mauro; Bruner-Klisovic, Rebecca; Caligiuri, Michael A.; Bloomfield, Clara D. (November 2005). "The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein". Cancer Cell. 8 (5): 355–368. doi:10.1016/j.ccr.2005.10.015. PMID 16286244.
  29. ^ Trotta, Rossana; Vignudelli, Tatiana; Candini, Olivia; Intine, Robert V.; Pecorari, Luisa; Guerzoni, Clara; Santilli, Giorgia; Byrom, Mike W.; Goldoni, Silvia; Ford, Lance P.; Caligiuri, Michael A.; Maraia, Richard J.; Perrotti, Danilo; Calabretta, Bruno (February 2003). "BCR/ABL activates mdm2 mRNA translation via the La antigen". Cancer Cell. 3 (2): 145–160. doi:10.1016/S1535-6108(03)00020-5. PMID 12620409.
  30. ^ a b Hao, Qian; Chen, Jiaxiang; Lu, Hua; Zhou, Xiang (2023-03-29). Yao, Xuebiao (ed.). "The ARTS of p53-dependent mitochondrial apoptosis". Journal of Molecular Cell Biology. 14 (10). doi:10.1093/jmcb/mjac074. ISSN 1674-2788. PMC 10053023. PMID 36565718.
  31. ^ Gong, JianGen; Costanzo, Antonio; Yang, Hong-Qiong; Melino, Gerry; Kaelin, William G.; Levrero, Massimo; Wang, Jean Y. J. (June 1999). "The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage". Nature. 399 (6738): 806–809. Bibcode:1999Natur.399..806G. doi:10.1038/21690. ISSN 0028-0836. PMID 10391249.
  32. ^ Yuan, Zhi-Min; Shioya, Hisashi; Ishiko, Takatoshi; Sun, Xiangao; Gu, Jijie; Huang, YinYin; Lu, Hua; Kharbanda, Surender; Weichselbaum, Ralph; Kufe, Donald (1999-06-24). "p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage". Nature. 399 (6738): 814–817. Bibcode:1999Natur.399..814Y. doi:10.1038/21704. ISSN 0028-0836. PMID 10391251.
  33. ^ Alam, Manzar; Alam, Shoaib; Shamsi, Anas; Adnan, Mohd; Elasbali, Abdelbaset Mohamed; Al-Soud, Waleed Abu; Alreshidi, Mousa; Hawsawi, Yousef MohammedRabaa; Tippana, Anitha; Pasupuleti, Visweswara Rao; Hassan, Md. Imtaiyaz (2022-03-25). "Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer". Frontiers in Oncology. 12. doi:10.3389/fonc.2022.869672. ISSN 2234-943X. PMC 8990771. PMID 35402265.
  34. ^ Dumon, S; Santos, S Constantino Rosa; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F (1999-07-22). "IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line". Oncogene. 18 (29): 4191–4199. doi:10.1038/sj.onc.1202796. ISSN 0950-9232. PMID 10435632.
  35. ^ Koo, Nayeong; Sharma, Arun K.; Narayan, Satya (2022-04-30). "Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death". International Journal of Molecular Sciences. 23 (9): 5005. doi:10.3390/ijms23095005. ISSN 1422-0067. PMC 9103871. PMID 35563397.
  36. ^ Fernandez-Luna, J. L. (2000). "Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells". Apoptosis. 5 (4): 315–318. doi:10.1023/A:1009623222534. PMID 11227211.
  37. ^ Aboul-Soud, Mourad A. M.; Alzahrani, Alhussain J.; Mahmoud, Amer (2021-01-01). "Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing". Saudi Journal of Biological Sciences. 28 (1): 628–634. Bibcode:2021SJBS...28..628A. doi:10.1016/j.sjbs.2020.10.052. ISSN 1319-562X. PMC 7783809. PMID 33424349.
  38. ^ a b Sattler, Martin; Griffin, James D. (2001-04-01). "Mechanisms of Transformation by the BCR/ABL Oncogene". International Journal of Hematology. 73 (3): 278–291. doi:10.1007/BF02981952. ISSN 1865-3774. PMID 11345193.
  39. ^ a b c Senapati, Jayastu; Sasaki, Koji; Issa, Ghayas C.; Lipton, Jeffrey H.; Radich, Jerald P.; Jabbour, Elias; Kantarjian, Hagop M. (2023-04-24). "Management of chronic myeloid leukemia in 2023 – common ground and common sense". Blood Cancer Journal. 13 (1): 58. doi:10.1038/s41408-023-00823-9. ISSN 2044-5385. PMC 10123066. PMID 37088793.
  40. ^ Panjarian, Shoghag; Iacob, Roxana E.; Chen, Shugui; Engen, John R.; Smithgall, Thomas E. (2013-02-22). "Structure and Dynamic Regulation of Abl Kinases*". Journal of Biological Chemistry. 288 (8): 5443–5450. doi:10.1074/jbc.R112.438382. ISSN 0021-9258. PMC 3581414. PMID 23316053.
  41. ^ a b c d e f g Jabbour, Elias; Kantarjian, Hagop (2025-03-17). "Chronic Myeloid Leukemia: A Review". JAMA. doi:10.1001/jama.2025.0220. ISSN 0098-7484. PMID 40094679.
  42. ^ Ortiz-Hidalgo, Carlos (2025-03-19). "History of Leukemia, Revisited". Current Oncology Reports. doi:10.1007/s11912-025-01658-2. ISSN 1534-6269. PMID 40106215.
  43. ^ Rudkin, George T.; Hungerford, David A.; Nowell, Peter C. (1964-06-05). "DNA Contents of Chromosome Ph1 and Chromosome 21 in Human Chronic Granulocytic Leukemia". Science. 144 (3623): 1229–1232. doi:10.1126/science.144.3623.1229. PMID 14150328.
  44. ^ a b c Chandra, H. Sharat; Heisterkamp, Nora C.; Hungerford, Alice; Morrissette, Jennifer J. D.; Nowell, Peter C.; Rowley, Janet D.; Testa, Joseph R. (2011-04-01). "Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome". Cancer Genetics. 204 (4): 171–179. doi:10.1016/j.cancergen.2011.03.002. ISSN 2210-7762. PMC 3092778. PMID 21536234.
  45. ^ a b Koretzky, Gary A. (2007-08-01). "The legacy of the Philadelphia chromosome". The Journal of Clinical Investigation. 117 (8): 2030–2032. doi:10.1172/JCI33032. ISSN 0021-9738. PMC 1934583. PMID 17671635.
  46. ^ Nowell, Peter C. (2007-08-01). "Discovery of the Philadelphia chromosome: a personal perspective". The Journal of Clinical Investigation. 117 (8): 2033–2035. doi:10.1172/JCI31771. ISSN 0021-9738. PMC 1934591. PMID 17671636.
  47. ^ Groffen, John; Stephenson, John R.; Heisterkamp, Nora; Klein, Annelies de; Bartram, Claus R.; Grosveld, Gerard (1984-01-01). "Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22". Cell. 36 (1): 93–99. doi:10.1016/0092-8674(84)90077-1. ISSN 0092-8674. PMID 6319012.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Philadelphia_chromosome&oldid=1283310067"